Oncternal Therapeutics (ONCT)

Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q1 2020 Results - Earnings Call Trans
May 10, 2020 | Price: Free! | Source: Seeking Alpha

Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q4 2019 Results - Earnings Call Trans
March 17, 2020 | Price: Free! | Source: Seeking Alpha

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2019 Results - Earnings Call Transcr
Nov. 10, 2019 | Price: Free! | Source: Seeking Alpha

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2019 Results - Earnings Call Transcr
Aug. 11, 2019 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q4 2015 Results - Earnings Call Webcast
March 3, 2016 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript
March 3, 2016 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q3 2015 Results - Earnings Call Transcript
Oct. 29, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q3 2015 Results - Earnings Call Webcast
Oct. 29, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q2 2015 Results - Earnings Call Transcript
Aug. 6, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q2 2015 Results - Earnings Call Webcast
Aug. 6, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q1 2015 Results - Earnings Call Transcript
May 8, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q4 2014 Results - Earnings Call Transcript
March 4, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q3 2014 Results - Earnings Call Webcast
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q3 2014 Results - Earnings Call Transcript
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 4, 2014 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2013 Earnings Conference Call Transcript
Nov. 12, 2013 | Price: $106.00 | Source: Thomson

GTx, Inc. Discusses Q2 2013 Results (Webcast)
Nov. 12, 2013 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 12, 2013 | Price: Free! | Source: Seeking Alpha

GTx POWER Trials Results Conference Call Transcript
Aug. 19, 2013 | Price: $106.00 | Source: Thomson

GTx's CEO Presents at GTx POWER Trials Results Conference (Transcript)
Aug. 19, 2013 | Price: Free! | Source: Seeking Alpha

GTx, Inc. - Business Update Call Transcript
Aug. 19, 2013 | Price: Free! | Source: Earnings Impact

GTx, Inc. Q1 2013 Earnings Conference Call Transcript
May 3, 2013 | Price: $106.00 | Source: Thomson

GTx Inc.'s CEO Discusses Q1 2013 Results - Earnings Call Transcript
May 3, 2013 | Price: Free! | Source: Seeking Alpha

GTx's Management Presents at Citi Global Healthcare - Transcript
Feb. 25, 2013 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Feb. 21, 2013 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q4 2012 Earnings Conference Call Transcript
Feb. 21, 2013 | Price: $106.00 | Source: Thomson

GTx, Inc. Analyst Day Transcript
Feb. 15, 2013 | Price: $106.00 | Source: Thomson

GTx's CEO Hosts Analyst Day Conference (Transcript)
Feb. 15, 2013 | Price: Free! | Source: Seeking Alpha

GTX's CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Nov. 13, 2012 | Price: Free! | Source: Seeking Alpha

GTx Incorporated's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 8, 2012 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2012 Earnings Conference Call Transcript
Nov. 8, 2012 | Price: $106.00 | Source: Thomson

GTx's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Aug. 8, 2012 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q2 2012 Earnings Conference Call Transcript
Aug. 8, 2012 | Price: $54.00 | Source: Thomson

GTx, Inc. Q1 2012 Earnings Conference Call Transcript
May 8, 2012 | Price: $54.00 | Source: Thomson

GTx, Inc. Q4 2011 Earnings Conference Call Transcript
Feb. 21, 2012 | Price: $54.00 | Source: Thomson

GTx Inc Q4 2008 Earnings Call Transcript
Feb. 17, 2009 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2008 Earnings Call Transcript
Nov. 19, 2008 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q2 2008 Earnings Call Transcript
Sept. 8, 2008 | Price: Free! | Source: Seeking Alpha

GTx Inc. Q1 2008 Earnings Call Transcript
May 12, 2008 | Price: Free! | Source: Seeking Alpha

GTx Q4 2007 Earnings Call Transcript
Feb. 19, 2008 | Price: Free! | Source: Seeking Alpha

Recent filings

The Company reported a - June 30, 2020

Current report, item 5.07 - June 15, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Oncternal Therapeutics director just declared 0 options - June 12, 2020

Notice of Exempt Offering of Securities, item 06b - June 3, 2020

Steven Boyd just provided an update on share ownership of Oncternal Therapeutics - May 29, 2020

Oncternal Therapeutics director just picked up 17,412 shares - May 22, 2020

Oncternal Therapeutics just filed a prospectus, suggesting it plans to soon issue some securities - May 21, 2020

Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering - May 21, 2020

On May - May 19, 2020

Oncternal Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - May 7, 2020

Oncternal Provides Business Update And Announces First Quarter 2020 Financial Results - May 7, 2020

Oncternal: Form, Schedule Or Registration Statement No Filing Party: Date Filed: - April 29, 2020

Oncternal Therapeutics releases salary data. CEO sees compensation rise 115% - April 29, 2020

Current report, item 8.01 - April 2, 2020

Oncternal Therapeutics's Chief Executive Officer just declared 0 options - March 18, 2020

Current report, item 5.08 - March 18, 2020

Oncternal Therapeutics's Chief Financial Officer just declared 0 options - March 18, 2020

Oncternal Therapeutics's Chief Business Officer just declared 0 options - March 18, 2020

Oncternal Therapeutics's Chief Medical Officer just declared 0 options - March 18, 2020

Oncternal Therapeutics's Legal Counsel just declared 0 options - March 18, 2020

Oncternal Therapeutics's Chief Scientific Officer just declared 0 options - March 18, 2020

Oncternal Provides Business Update And Announces Fourth Quarter And Full Year 2019 Financial Results - March 16, 2020

Oncternal Therapeutics Just Filed Its Annual Report: Net Loss Per Share B... - March 16, 2020

Perceptive Life Sciences Master Fund, Ltd. just issued a filing suggesting it has sold all of its Oncternal Therapeutics - Feb. 14, 2020

Current report, items 7.01 and 9.01 - Jan. 13, 2020

Oncternal Therapeutics's Chief Executive Officer just declared 0 options - Jan. 9, 2020

Current report, item 8.01 - Dec. 31, 2019

Oncternal Therapeutics director just declared ownership of no shares of Oncternal Therapeutics - Dec. 23, 2019

Oncternal Therapeutics director just declared 0 options - Dec. 23, 2019

Departure of Directors or Certain - Dec. 23, 2019

On December - Dec. 13, 2019

On December - Dec. 9, 2019

Oncternal Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - Nov. 8, 2019

Oncternal Reports Third Quarter 2019 Financial Results And Provides Business Update - Nov. 7, 2019

Current report, items 7.01, 8.01, and 9.01 - Oct. 3, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Chief Executive Officer just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Chief Financial Officer just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Legal Counsel just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Chief Scientific Officer just declared 0 options - Sept. 9, 2019

Oncternal Therapeutics's Chief Business Officer just declared ownership of no shares of Oncternal Therapeutics - Sept. 9, 2019

Oncternal Therapeutics's Chief Scientific Officer just declared ownership of no shares of Oncternal Therapeutics - Sept. 9, 2019

Oncternal Therapeutics's Chief Business Officer just declared 0 options - Sept. 9, 2019

Oncternal Therapeutics's Chief Medical Officer just declared 0 options - Aug. 28, 2019

Oncternal Therapeutics's Chief Medical Officer just declared ownership of no shares of Oncternal Therapeutics - Aug. 28, 2019

Securities to be offered to employees in employee benefit plans - Aug. 15, 2019

Oncternal: Index To Unaudited Interim Condensed Consolidated Financial Statements Condensed Financial Statements Condensed Consolidated Balance Sheets - Aug. 9, 2019

Oncternal Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - Aug. 9, 2019

Oncternal Reports Second Quarter 2019 Financial Results And Provides Business Update - Aug. 8, 2019

Joseph R. Hyde, III just provided an update on activist position in Oncternal Therapeutics - Aug. 1, 2019

Changes in Registrants Certifying - June 20, 2019

President of Oncternal Therapeutics was just granted 42,196 options - June 20, 2019

Shanghai Pharmaceuticals Holding Co., Ltd. just provided an update on activist position in GTx - June 17, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just picked up 26,174 shares - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx's General Counsel just declared ownership of no shares of GTx - June 11, 2019

GTx director just picked up 717,752 shares - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

Major owner of GTx just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

President of GTx just declared ownership of no shares of GTx - June 11, 2019

GTx's Chief Financial Officer just declared ownership of no shares of GTx - June 11, 2019

GTx's General Counsel just picked up 9,299 shares - June 11, 2019

President of GTx just picked up 277,868 shares - June 11, 2019

GTx director just picked up 14,677 shares - June 11, 2019

GTx's Chief Financial Officer just picked up 48,988 shares - June 11, 2019

Major owner of GTx just picked up 2,495,114 shares - June 11, 2019

Oncternal Therapeutics Completes Reverse Merger With Gtx, Inc - June 10, 2019

Submission of Matters to a Vote of Security - June 5, 2019

Prospectuses and communications, business combinations - June 3, 2019

Important information concerning the Merger and the transactions contemplated by the Merger Agreement is set forth in the Joint Proxy - May 24, 2019

Prospectuses and communications, business combinations - May 24, 2019

Prospectuses and communications, business combinations - May 16, 2019

GTx Just Filed Its Quarterly Report: 4.   Basic and Di... - May 10, 2019

GTx Just Received a Notice of Effectiveness - May 7, 2019

Registration of securities, business combinations - May 6, 2019

Entry into a Material Definitive - April 30, 2019

GTx: Documents Incorporated By Reference         None. EXPLANATORY NOTE - April 30, 2019

Prospectuses and communications, business combinations - April 30, 2019

Registration of securities, business combinations - April 8, 2019

GTx Just Filed Its Annual Report:   Basic and Dil... - March 18, 2019

Prospectuses and communications, business combinations - March 7, 2019

Prospectuses and communications, business combinations - March 7, 2019

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. HYDE JOSEPH R III 57,046,500 N/A April 2, 2015
2. Pyramid Peak Foundation 55,078,934 N/A April 2, 2015
3. Jack W. Schuler 12,246,208 N/A Nov. 3, 2015
4. Walter Rotchild 7,750,213 N/A Dec. 31, 2015
5. Formanek Investment Trust 7,400,000 N/A April 2, 2015
6. Creative Planning 487,737 N/A March 31, 2020
7. BlackRock Institutional Trust Company, N.A. 152,872 N/A Dec. 31, 2016
8. DOWLING & YAHNKE LLC 150,464 N/A March 31, 2020
9. REGENTS OF THE UNIVERSITY OF CALIFORNIA 107,108 N/A March 31, 2020
10. UNITED CAPITAL FINANCIAL ADVISERS, LLC 84,605 N/A March 31, 2020
11. Aureus Asset Management, LLC 70,211 N/A March 31, 2020
12. MILLENNIUM MANAGEMENT LLC 65,278 N/A March 31, 2020
13. VANGUARD GROUP INC 31,782 N/A June 30, 2019
14. RENAISSANCE TECHNOLOGIES LLC 27,317 N/A March 31, 2020
15. State Street Corp 23,299 N/A March 31, 2020
16. J.P. Turner & Co Capital Mnagement, LLC 21,300 N/A June 30, 2015
17. NORTHERN TRUST CORP 18,705 N/A March 31, 2018
18. BlackRock Advisors LLC 17,845 N/A Sept. 30, 2016
19. GEODE CAPITAL MANAGEMENT, LLC 17,773 N/A March 31, 2020
20. Cohen Capital Management, Inc. 13,046 N/A March 31, 2020
21. BlackRock Fund Advisors 9,421 N/A Sept. 30, 2016
22. MEEDER ASSET MANAGEMENT INC 4,644 N/A Dec. 31, 2019
23. JPMORGAN CHASE & CO 4,113 N/A Sept. 30, 2017
24. North Star Investment Management Corp. 4,000 N/A March 31, 2020
25. VICTORY CAPITAL MANAGEMENT INC 2,049 N/A March 31, 2020
26. MORGAN STANLEY 359 N/A Dec. 31, 2016
27. GROUP ONE TRADING, L.P. 191 N/A March 31, 2020
28. GROUP ONE TRADING, L.P. 191 N/A Dec. 31, 2019
29. BANK OF AMERICA CORP /DE/ 143 N/A Sept. 30, 2017
30. MORGAN STANLEY 81 N/A Sept. 30, 2017
 


Feedback